LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Back to previous search Search history
Advanced search

Your last searches

  1. AU="Wang, Jiuzhou"
  2. AU=de Oliveira Andrade Rodrigo
  3. AU="Tran, Nham"
  4. AU="Zdrodowska, Kinga"
  5. AU="Kulkarni, Yogesh A"
  6. AU=Manna Sounik
  7. AU="Aftab, Raiyyan"
  8. AU="Vaurynovich, S"
  9. AU="Arregle, Florent"
  10. AU="Won, Gayeon"
  11. AU="Kopp, Jeffrey B"
  12. AU="Cano-Vega, M"

Search results

Result 1 - 10 of total 21

Search options

  1. Article ; Online: Multiple augmented reduced rank regression for pan-cancer analysis.

    Wang, Jiuzhou / Lock, Eric F

    Biometrics

    2024  Volume 80, Issue 1

    Abstract: Statistical approaches that successfully combine multiple datasets are more powerful, efficient, and scientifically informative than separate analyses. To address variation architectures correctly and comprehensively for high-dimensional data across ... ...

    Abstract Statistical approaches that successfully combine multiple datasets are more powerful, efficient, and scientifically informative than separate analyses. To address variation architectures correctly and comprehensively for high-dimensional data across multiple sample sets (ie, cohorts), we propose multiple augmented reduced rank regression (maRRR), a flexible matrix regression and factorization method to concurrently learn both covariate-driven and auxiliary structured variations. We consider a structured nuclear norm objective that is motivated by random matrix theory, in which the regression or factorization terms may be shared or specific to any number of cohorts. Our framework subsumes several existing methods, such as reduced rank regression and unsupervised multimatrix factorization approaches, and includes a promising novel approach to regression and factorization of a single dataset (aRRR) as a special case. Simulations demonstrate substantial gains in power from combining multiple datasets, and from parsimoniously accounting for all structured variations. We apply maRRR to gene expression data from multiple cancer types (ie, pan-cancer) from The Cancer Genome Atlas, with somatic mutations as covariates. The method performs well with respect to prediction and imputation of held-out data, and provides new insights into mutation-driven and auxiliary variations that are shared or specific to certain cancer types.
    MeSH term(s) Humans ; Multivariate Analysis ; Neoplasms/genetics
    Language English
    Publishing date 2024-01-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 213543-7
    ISSN 1541-0420 ; 0099-4987 ; 0006-341X
    ISSN (online) 1541-0420
    ISSN 0099-4987 ; 0006-341X
    DOI 10.1093/biomtc/ujad002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 72: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Multiple Augmented Reduced Rank Regression for Pan-Cancer Analysis.

    Wang, Jiuzhou / Lock, Eric F

    ArXiv

    2023  

    Abstract: Statistical approaches that successfully combine multiple datasets are more powerful, efficient, and scientifically informative than separate analyses. To address variation architectures correctly and comprehensively for high-dimensional data across ... ...

    Abstract Statistical approaches that successfully combine multiple datasets are more powerful, efficient, and scientifically informative than separate analyses. To address variation architectures correctly and comprehensively for high-dimensional data across multiple sample sets (i.e., cohorts), we propose multiple augmented reduced rank regression (maRRR), a flexible matrix regression and factorization method to concurrently learn both covariate-driven and auxiliary structured variation. We consider a structured nuclear norm objective that is motivated by random matrix theory, in which the regression or factorization terms may be shared or specific to any number of cohorts. Our framework subsumes several existing methods, such as reduced rank regression and unsupervised multi-matrix factorization approaches, and includes a promising novel approach to regression and factorization of a single dataset (aRRR) as a special case. Simulations demonstrate substantial gains in power from combining multiple datasets, and from parsimoniously accounting for all structured variation. We apply maRRR to gene expression data from multiple cancer types (i.e., pan-cancer) from TCGA, with somatic mutations as covariates. The method performs well with respect to prediction and imputation of held-out data, and provides new insights into mutation-driven and auxiliary variation that is shared or specific to certain cancer types.
    Language English
    Publishing date 2023-08-30
    Publishing country United States
    Document type Preprint
    ISSN 2331-8422
    ISSN (online) 2331-8422
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Deep IDA: A Deep Learning Method for Integrative Discriminant Analysis of Multi-View Data with Feature Ranking-An Application to COVID-19 severity.

    Wang, Jiuzhou / Safo, Sandra E

    ArXiv

    2021  

    Abstract: COVID-19 severity is due to complications from SARS-Cov-2 but the clinical course of the infection varies for individuals, emphasizing the need to better understand the disease at the molecular level. We use clinical and multiple molecular data (or views) ...

    Abstract COVID-19 severity is due to complications from SARS-Cov-2 but the clinical course of the infection varies for individuals, emphasizing the need to better understand the disease at the molecular level. We use clinical and multiple molecular data (or views) obtained from patients with and without COVID-19 who were (or not) admitted to the intensive care unit to shed light on COVID-19 severity. Methods for jointly associating the views and separating the COVID-19 groups (i.e., one-step methods) have focused on linear relationships. The relationships between the views and COVID-19 patient groups, however, are too complex to be understood solely by linear methods. Existing nonlinear one-step methods cannot be used to identify signatures to aid in our understanding of the complexity of the disease. We propose Deep IDA (Integrative Discriminant Analysis) to address analytical challenges in our problem of interest. Deep IDA learns nonlinear projections of two or more views that maximally associate the views and separate the classes in each view, and permits feature ranking for interpretable findings. Our applications demonstrate that Deep IDA has competitive classification rates compared to other state-of-the-art methods and is able to identify molecular signatures that facilitate an understanding of COVID-19 severity.
    Language English
    Publishing date 2021-11-18
    Publishing country United States
    Document type Preprint
    ISSN 2331-8422
    ISSN (online) 2331-8422
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: Substantially Promoted Energy Density of Li||CFₓ Primary Battery Enabled by Li⁺-DMP Coordinated Structure

    Xiao, Yukang / Jian, Junhua / Fu, Ang / Tang, Chao / Zou, Yue / Chen, Xunxin / Wang, Jiuzhou / Yang, Yong / Zheng, Jianming

    ACS sustainable chemistry & engineering. 2022 May 05, v. 10, no. 19

    2022  

    Abstract: Carbon fluoride (CFx) has attracted worldwide attention due to its high theoretical energy density (over 2000 Wh kg–¹). However, the large electrochemical overpotential as resulted from the strong C–F covalent bond limits the full utilization of the ... ...

    Abstract Carbon fluoride (CFx) has attracted worldwide attention due to its high theoretical energy density (over 2000 Wh kg–¹). However, the large electrochemical overpotential as resulted from the strong C–F covalent bond limits the full utilization of the intrinsic energy from CFx. In this work, a N,N-dimethylpropionamide (DMP) (along with propylene carbonate (PC) cosolvent)-based electrolyte is designed to boost the discharge plateau of lithium (Li)||CFₓ batteries. It is revealed that DMP molecules have powerful nucleophilicity and a strong solvating ability with Li⁺ ions by its high donor number (DN), which significantly weakens the C–F covalent bond and thus promotes the discharge voltage plateau and energy density. The optimized electrolyte, 1 M lithium tetrafluoroborate (LiBF₄) dissolved in DMP and PC (8:2 in volume), achieves largely elevated discharge voltage plateau of 2.64 V (vs 2.41 V for carbonate-based electrolyte) and the superior energy density up to 2085 Wh kg–¹ (vs 1888 Wh kg–¹ for carbonate-based electrolyte) at a current density of 10 mA g–¹. The superior electrochemical performance of CFₓ in the optimized electrolyte is further confirmed in pouch-type cells. Meanwhile, the CFₓ shows less electrode volume expansion, and good calendar life during storage at 60 °C in the optimized electrolyte, which holds great promise for practical applications.
    Keywords Lewis bases ; batteries ; carbon ; carbonates ; chemical bonding ; electric potential difference ; electrochemistry ; electrodes ; energy density ; green chemistry ; lithium ; propylene
    Language English
    Dates of publication 2022-0505
    Size p. 6217-6229.
    Publishing place American Chemical Society
    Document type Article
    ISSN 2168-0485
    DOI 10.1021/acssuschemeng.1c08707
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Adjusting win statistics for dependent censoring.

    Dong, Gaohong / Huang, Bo / Wang, Duolao / Verbeeck, Johan / Wang, Jiuzhou / Hoaglin, David C

    Pharmaceutical statistics

    2020  Volume 20, Issue 3, Page(s) 440–450

    Abstract: For composite outcomes whose components can be prioritized on clinical importance, the win ratio, the net benefit and the win odds apply that order in comparing patients pairwise to produce wins and subsequently win proportions. Because these three ... ...

    Abstract For composite outcomes whose components can be prioritized on clinical importance, the win ratio, the net benefit and the win odds apply that order in comparing patients pairwise to produce wins and subsequently win proportions. Because these three statistics are derived using the same win proportions and they test the same hypothesis of equal win probabilities in the two treatment groups, we refer to them as win statistics. These methods, particularly the win ratio and the net benefit, have received increasing attention in methodological research and in design and analysis of clinical trials. For time-to-event outcomes, however, censoring may introduce bias. Previous work has shown that inverse-probability-of-censoring weighting (IPCW) can correct the win ratio for bias from independent censoring. The present article uses the IPCW approach to adjust win statistics for dependent censoring that can be predicted by baseline covariates and/or time-dependent covariates (producing the CovIPCW-adjusted win statistics). Theoretically and with examples and simulations, we show that the CovIPCW-adjusted win statistics are unbiased estimators of treatment effect in the presence of dependent censoring.
    MeSH term(s) Bias ; Computer Simulation ; Data Interpretation, Statistical ; Humans ; Probability ; Research Design
    Language English
    Publishing date 2020-11-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 2083706-9
    ISSN 1539-1612 ; 1539-1604
    ISSN (online) 1539-1612
    ISSN 1539-1604
    DOI 10.1002/pst.2086
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

    Gilbert, Lucy / Oaknin, Ana / Matulonis, Ursula A / Mantia-Smaldone, Gina M / Lim, Peter C / Castro, Cesar M / Provencher, Diane / Memarzadeh, Sanaz / Method, Michael / Wang, Jiuzhou / Moore, Kathleen N / O'Malley, David M

    Gynecologic oncology

    2023  Volume 170, Page(s) 241–247

    Abstract: Purpose: Evaluate the antitumor activity and safety profile of the combination of mirvetuximab soravtansine and bevacizumab in patients with platinum-resistant ovarian cancer.: Methods: Patients with recurrent epithelial ovarian, fallopian tube, or ... ...

    Abstract Purpose: Evaluate the antitumor activity and safety profile of the combination of mirvetuximab soravtansine and bevacizumab in patients with platinum-resistant ovarian cancer.
    Methods: Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose most recent platinum-free interval was ≤6 months, were administered mirvetuximab soravtansine (6 mg/kg adjusted ideal body weight) and bevacizumab (15 mg/kg), intravenously, once every 3 weeks. Eligibility included FRα expression by immunohistochemistry (IHC; ≥25% of cells with ≥2+ intensity). Prior bevacizumab and/or PARP inhibitor (PARPi) treatment were permitted. The primary endpoint was confirmed objective response rate (ORR). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and safety.
    Results: Ninety-four patients received combination treatment with mirvetuximab soravtansine and bevacizumab. Median age was 62 years (range, 39-81). Fifty-two percent had ≥3 prior therapies; 59% had prior bevacizumab; and 27% had prior PARPi. ORR was 44% (95% CI 33, 54) with 5 complete responses, median DOR 9.7 months (95% CI 6.9, 14.1), and median PFS 8.2 months (95% CI 6.8, 10.0). Treatment-related adverse events were consistent with the profiles of each agent, with the most common being blurred vision (all grades 57%; grade 3, 1%), diarrhea (54%; grade 3, 1%), and nausea (51%; grade 3, 1%).
    Conclusion: The mirvetuximab soravtansine plus bevacizumab doublet is an active and well-tolerated regimen in patients with FRα-expressing platinum-resistant ovarian cancer. Promising activity was observed for patients regardless of level of FRα expression or prior bevacizumab. These data underscore the potential for mirvetuximab soravtansine as the combination partner of choice for bevacizumab in this setting.
    MeSH term(s) Humans ; Female ; Middle Aged ; Bevacizumab/therapeutic use ; Ovarian Neoplasms/pathology ; Folate Receptor 1 ; Drug Resistance, Neoplasm ; Carcinoma, Ovarian Epithelial/drug therapy ; Immunoconjugates ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoplasm Recurrence, Local/drug therapy
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; mirvetuximab soravtansine (98DE7VN88D) ; Folate Receptor 1 ; Immunoconjugates ; Antineoplastic Agents
    Language English
    Publishing date 2023-02-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 801461-9
    ISSN 1095-6859 ; 0090-8258
    ISSN (online) 1095-6859
    ISSN 0090-8258
    DOI 10.1016/j.ygyno.2023.01.020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 885: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Boosting the Energy Density of Li||CF

    Fu, Ang / Xiao, Yukang / Jian, Junhua / Huang, Lin / Tang, Chao / Chen, Xunxin / Zou, Yue / Wang, Jiuzhou / Yang, Yong / Zheng, Jianming

    ACS applied materials & interfaces

    2021  Volume 13, Issue 48, Page(s) 57470–57480

    Abstract: Elevating the discharge voltage plateau is regarded as the most effective strategy to improve the energy density of Li|| ... ...

    Abstract Elevating the discharge voltage plateau is regarded as the most effective strategy to improve the energy density of Li||CF
    Language English
    Publishing date 2021-11-24
    Publishing country United States
    Document type Journal Article
    ISSN 1944-8252
    ISSN (online) 1944-8252
    DOI 10.1021/acsami.1c19016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article: Boosting the Energy Density of Li||CFₓ Primary Batteries Using a 1,3-Dimethyl-2-imidazolidinone-Based Electrolyte

    Fu, Ang / Xiao, Yukang / Jian, Junhua / Huang, Lin / Tang, Chao / Chen, Xunxin / Zou, Yue / Wang, Jiuzhou / Yang, Yong / Zheng, Jianming

    ACS applied materials & interfaces. 2021 Nov. 24, v. 13, no. 48

    2021  

    Abstract: Elevating the discharge voltage plateau is regarded as the most effective strategy to improve the energy density of Li||CFₓ batteries in consideration of the finite capacity of CFₓ (x ∼ 1) cathodes. Here, an electrolyte, with LiBF₄ in 1,3-dimethyl-2- ... ...

    Abstract Elevating the discharge voltage plateau is regarded as the most effective strategy to improve the energy density of Li||CFₓ batteries in consideration of the finite capacity of CFₓ (x ∼ 1) cathodes. Here, an electrolyte, with LiBF₄ in 1,3-dimethyl-2-imidazolidinone (DMI)/1,2-dimethoxyethane (DME), is developed for the first time to substantially promote the discharge voltage of CFₓ without compromising the available discharge capacity. DME possesses the property of low viscosity, while DMI functions to increase the voltage plateau during discharge owing to its moderate nucleophilicity and donor number, which decreases the energy barrier for breaking C–F bonds. The optimized electrolyte exhibits a significantly high average discharge voltage of 2.69 V at a current density of 10 mA g–¹, which is 11.6% higher than the control electrolyte (2.41 V). In addition, a high energy density of 2099 Wh kg–¹ is achieved in the optimized electrolyte (vs 1905 Wh kg–¹ in the control electrolyte), showing great potential for practical applications.
    Keywords Lewis bases ; electric potential difference ; electrolytes ; energy density ; viscosity
    Language English
    Dates of publication 2021-1124
    Size p. 57470-57480.
    Publishing place American Chemical Society
    Document type Article
    ISSN 1944-8252
    DOI 10.1021/acsami.1c19016
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Reply to Z.R. McCaw et al.

    Matulonis, Ursula A / Lorusso, Domenica / Oaknin, Ana / Pignata, Sandro / Dean, Andrew / Denys, Hannelore / Colombo, Nicoletta / Van Gorp, Toon / Konner, Jason A / Marin, Margarita Romeo / Harter, Philipp / Murphy, Conleth G / Wang, Jiuzhou / Noble, Elizabeth / Esteves, Brooke / Method, Michael / Coleman, Robert L

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2023  Volume 41, Issue 29, Page(s) 4705–4706

    Language English
    Publishing date 2023-08-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.23.00752
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.

    Matulonis, Ursula A / Lorusso, Domenica / Oaknin, Ana / Pignata, Sandro / Dean, Andrew / Denys, Hannelore / Colombo, Nicoletta / Van Gorp, Toon / Konner, Jason A / Marin, Margarita Romeo / Harter, Philipp / Murphy, Conleth G / Wang, Jiuzhou / Noble, Elizabeth / Esteves, Brooke / Method, Michael / Coleman, Robert L

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2023  Volume 41, Issue 13, Page(s) 2436–2445

    Abstract: Purpose: Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor α (FRα). ... ...

    Abstract Purpose: Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor α (FRα). SORAYA is a single-arm, phase II study evaluating efficacy and safety of MIRV in patients with PROC.
    Methods: SORAYA enrolled FRα-high patients with PROC who had received one to three prior therapies, including required bevacizumab. The primary end point was confirmed objective response rate (ORR) by investigator; duration of response was the key secondary end point.
    Results: One hundred six patients were enrolled; 105 were evaluable for efficacy. All patients had received prior bevacizumab, 51% had three prior lines of therapy, and 48% received a prior poly ADP-ribose polymerase inhibitor. Median follow-up was 13.4 months. ORR was 32.4% (95% CI, 23.6 to 42.2), including five complete and 29 partial responses. The median duration of response was 6.9 months (95% CI, 5.6 to 9.7). In patients with one to two priors, the ORR by investigator was 35.3% (95% CI, 22.4 to 49.9) and in patients with three priors was 30.2% (95% CI, 18.3 to 44.3). The ORR by investigator was 38.0% (95% CI, 24.7 to 52.8) in patients with prior poly ADP-ribose polymerase inhibitor exposure and 27.5% (95% CI, 15.9 to 41.7) in those without. The most common treatment-related adverse events (all grade and grade 3-4) were blurred vision (41% and 6%), keratopathy (29% and 9%), and nausea (29% and 0%). Treatment-related adverse events led to dose delays, reductions, and discontinuations in 33%, 20%, and 9% of patients, respectively.
    Conclusion: MIRV demonstrated consistent clinically meaningful antitumor activity and favorable tolerability and safety in patients with FRα-high PROC who had received up to three prior therapies, including bevacizumab, representing an important advance for this biomarker-selected population.
    MeSH term(s) Humans ; Female ; Carcinoma, Ovarian Epithelial/drug therapy ; Bevacizumab/therapeutic use ; Ovarian Neoplasms/drug therapy ; Folate Receptor 1/therapeutic use ; Immunoconjugates/adverse effects ; Antineoplastic Agents/therapeutic use ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Adenosine Diphosphate Ribose/therapeutic use
    Chemical Substances mirvetuximab soravtansine (98DE7VN88D) ; Bevacizumab (2S9ZZM9Q9V) ; Folate Receptor 1 ; Immunoconjugates ; Antineoplastic Agents ; Poly(ADP-ribose) Polymerase Inhibitors ; Adenosine Diphosphate Ribose (20762-30-5)
    Language English
    Publishing date 2023-01-30
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.22.01900
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top